TSH receptor antibodies in breast cancer and benign breast disease: a hospital based study

Jawahar Krishnaswamy; Reshma Sattar

doi:10.18203/2349-2902.isj20175397

Authors

Jawahar Krishnaswamy Department of General Surgery, Saveetha Medical College, Chennai, Tamil Nadu, India
Reshma Sattar Department of General Surgery, Saveetha Medical College, Chennai, Tamil Nadu, India

DOI:

https://doi.org/10.18203/2349-2902.isj20175397

Keywords:

Breast cancer, Benign breast tumours, TSH receptor antibody, TSH

Abstract

Background: Associations between breast cancer, benign breast tumours and thyroid disorders are reported in numerous studies. Relationship between thyroperoxidase antibodies (TPOAb), thyroglobulin antibodies (TgAb), and breast cancer have been previously demonstrated. However, no analysis has been performed concerning an association between thyrotropin (TSH) receptor antibodies (TSHRAb) and breast cancer. The aim of the study was to evaluate the presence of TSH Receptor antibodies in women with breast cancer or benign breast tumours, and to analyze a possible relationship between TSH Receptor antibodies, and these two groups of breast diseases with emphasis to laboratory findings.

Methods: Clinical and laboratory details of 87 women hospitalized were prospectively analyzed, using an Post hoc Tukey HSD for normally distributed continuous data, chi-square test for comparison.

Results: TSH Receptor antibody levels in breast cancer was statistically significant. We observed TSHRAb more frequently in patients with breast cancer. We found that TSHRAb is the only variable possessing as a prognostic marker for breast cancer.

Conclusions: The present study indicates that the serum levels of TSH Receptor Antibody are significant higher in patients with Breast cancer. These results have implications not only for the screening of patients but also for the development of new prognostic markers. Further high-quality prospective studies are needed to explore whether TSH Receptor Antibodies are potential prognostic markers for patients with Breast cancer.

Metrics

Metrics Loading ...

References

Ferlay J, Bray F, Sankila R, Parkin D. GLOBOCAN 2002. Cancer incidence, mortality and prevalence worldwide, version 2.0.2004; IARC press; Lyon. Available at http://ci.nii.ac.jp/naid/10029456013/.

Dinda S, Sanchez A, Moudgil V. Estrogen-like effects of thyroid hormone on the regulation of tumor suppressor proteins, P53 and retinoblastoma, in breast cancer cells. Oncogene. 2002;21:761-8.

Conde I, Paniagua R, Zamora J, Blanquez MJ, fraile B, Ruiz A, et al. Influence of thyroid hormone receptors on breast cancer cell proliferation. Ann Oncol. 2006;17:60-4.

Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, et al. Favourable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest. 2007;30(9):734-8.

Turken O, Narln Y, Demlrbas S, Onde ME, Sanyan O, Kandemlr EG, et al. Breast cancer in association with thyroid disorders. Breast Cancer Res. 2003;5:R110-3.

Hellevik Al, Asvold Bo, BJoro T, Romundstad PR, Nilsen TI, Vatten LJ. Thyroid function and cancer risk: a prospective population study cancer Epidemiol Biomarkers Prev. 2009;18:570-4.

Tosovic A, Bondeson AG, Bondeson L, Ericsson UB, Malm J, Manjer J. prospectively measured triiodothyronine levels are positively associated with breast cancer risk in post-menopausal women. Breast Cancer Res. 2010;12:R33.

Siegler JE, Lix, Jones SD, Kandil E. Early-onset breast cancer in a woman with Graves’s disease. Int J Clin Exp Med. 2012;5:358-62.

Rasmussson B, Feldt-Rasmussen U, Hegedus L, Perrild H, Bech K, Hoier-madsen M. Thyroid function in patients with breast cancer. Eur J Cancer Clin Oncol. 1987;23:553-6.

Coebergh JWW, Janssen-Heijnen MLG, Louwman WJ, Voogd AC, eds. Cancer incidence, care and survival in the south of the Netherlands 1995-1999: A Report of the Eindhoven cancer Registry with cross-border implications 2001. Comprehensive cancer centre south (1kz), Eindhoven.

Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the Nurse’s Health study. J Natl Cancer Inst. 2001;93:1563-8.

Smyth PPA, Shering SG, Kilbane MT, Murray MJ, Mc Dermot EWN, Smith Df. Serum thyroid peroxidise antibodies, thyroid volume, and outcome in breast carcinoma. J Clin Endocrinol Metab. 1998;83:2711-6.

Shering SG, Zbar AP, Moriarty M, McDermott EWM, O’ Higgins NJ, Smith PPA. Thyroid disorders and breast cancer. Eur J Cancer Pre. 1996;5:504-6.

Oh HJ, Chung JK, Kang JH, Kang WJ, NohDy, Park IA. The relationship between expression of the sodium/iodide symporter gene and the status of hormonal receptors in human breast cancer tissue. Cancer Res Treat. 2005;37:247-50.

Munoz JM, Gorman CA, Elveback LR, Wentz JR. Incidence of malignant neoplasms of all types of patients with Grave’s disease. Arch Intern Med. 1978;138:944-7.

Chen YK, Lin CL, Chang YJ, Cheng FT, Peng CL, Sung FC, et al. Cancer risk in patients with Grave’s disease: a nationwide cohort study. Thyroid. 2013;23(7):879-84.

Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012;133:1169-77.

Venturi S. Is there a role for iodine in breast diseases? Breast. 2001;10:379-82.

Jiskra J, Limanova Z, Barkmanova J, Smutek D, Fried Mannova Z. Autoimmune thyroid diseases in women with breast cancer and colorectal cancer. Pysiol Res. 2004;53:693-702.

Smyth PP. The thyroid, iodine and Breast cancer. Breast Cancer Res. 2003;5:235-8.

Giani C, Fierabracci P, Bonacci R, Gigliotti A, Campani D, De Negri F. Relationship between breast cancer and thyroid disease: relevance of autoimmune thyroid disorders in breast malignancy. J Clin Endocrinol Metab. 1996;81:990-4.

Smyth PPA, Shering S, Kilbane MT, Murray MJ, Mc Dermott EWM, Smith DF, et al. Serum thyroid peroxidase autoantibodies, thyroid volume, and outcome in breast cancer. J Clin Endocrinol Metab. 1998;83:2711-6.

Kuijpens JL, Nyklictek I, Louwman MW, Weetman TA, Pop VJ, Coebergn JW. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid. 2005;15:1253-9.

Simon MS, Tang MT, Bernstein L, Norman SA, Weiss L, Burkman RT, et al. Do thyroid disorders increase the risk of breast cancer? Cancer Epidemiol Biomarkers Prev. 2002;11:1574-8.

Latif R, Morshed SA, Zaidi M, Davies TF. The thyroid-stimulating hormone receptor: Impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signalling. Endocrinol Metab Clin North AM. 2009;38:319-41.

Zygmunt A, Adamczewski Z, Wojciechowska- Durczynska K, Cyniak-Magierska A, Krawczyk- Rusiecka K, et al. Evaluation of efficacy of iodine prophylaxis in Poland based on the examination of school children living in apoczno Town (Lodz Voivod ship). Thyroid Res. 2012;5:23.

Mittra I, Perrin J, Kumaoka S. Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer. BMJ. 1976;1:257-9.

Beyer SJ, Jimenez RE, Shapiro CL, Cho JY, Jhiang SM. Do cell surface trafficking impairments account for variable cell surface sodium iodide symporter levels in breast cancer? Breast Cancer Res Treat. 2009;115:205-12.

Davies TF. The thyrotrophin receptors spread themselves around. J Clin Endocrinol Metabol. 1994;79:1232-8.

Dumont JE, Meanhaut C. Growth factors controlling the thyroid gland. Baillieres Clin Endocrinnol Metabol. 1991;5:727-53.

Ali A, Mir MR, Bashir S, Hassan T, Bhat SA. Relationship between the levels of serum Thyroid Hormones and the Risk of Breast cancer. J Biol Agr Health C. 2011;2:56-60.

Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C. Thyroid function in breast cancer patients. Anticancer Res. 2010;30:1713-7.

Szychta P, Szychta W, Gesing A, Lewiński A, Karbownik-Lewińska M. TSH receptor antibodies have predictive value for breast cancer–retrospective analysis. Thyroid Research. 2013;6(1):8.